STOCK TITAN

Ionis Pharmaceuticals Inc - IONS STOCK NEWS

Welcome to our dedicated news page for Ionis Pharmaceuticals (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ionis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ionis Pharmaceuticals's position in the market.

Rhea-AI Summary
Ionis Pharmaceuticals reports positive Phase 3 data, financial guidance for 2024, and upcoming regulatory decisions for WAINUA™
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
earnings
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. receives Orphan Drug designation from the FDA for olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disease with high triglyceride levels and acute pancreatitis. The medicine aims to stabilize triglyceride levels and reduce the risk of life-threatening attacks, potentially becoming the standard of care in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
clinical trial
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. and AstraZeneca's eplontersen granted Fast Track designation by the FDA for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults. Eplontersen was previously approved for the treatment of hATTR-PN in the U.S. under the brand name WAINUA. The global CARDIO-TTRansform Phase 3 study of eplontersen is fully enrolled with more than 1,400 patients, with data expected as early as 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
clinical trial
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) will host a live webcast on February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results. The webcast can be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
earnings
-
Rhea-AI Summary
Vect-Horus, a biotechnology company, has entered into a global license agreement with Ionis Pharmaceuticals, Inc. The agreement provides Ionis with an exclusive license for a specified number of targets using Vect-Horus’ platform technology for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier. Vect-Horus will receive a double-digit million-dollar upfront payment, development, regulatory, and commercial milestone payments, and tiered single digit royalties on annual product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. announced positive Phase 3 OASIS-HAE study results for donidalorsen in treating hereditary angioedema, meeting primary endpoint with significant reduction in attack rate, favorable safety profile, and plans for FDA and EMA submissions. Donidalorsen targets prekallikrein to interrupt HAE attacks, with plans for independent drug launches and presentations of Phase 3 results at medical congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
clinical trial
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced their 2023 achievements and previewed important milestones for 2024, including U.S. approval of WAINUA™ and QALSODY® for serious diseases, positive Phase 3 trial readouts, and expansion of their late-stage pipeline to nine medicines in Phase 3 trials for 11 potential indications. They also made advances in their technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
Rhea-AI Summary
Alcyone Therapeutics Inc. (Alcyone) announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System (ThecaFlex) subcutaneous port and intrathecal catheter system for repeat intrathecal access, cerebrospinal fluid (CSF) aspiration, and delivery of SPINRAZA® (nusinersen) in spinal muscular atrophy (SMA) patients. The ThecaFlex device has the potential to significantly benefit patients with SMA who are being treated with SPINRAZA and are resistant to lumbar punctures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
clinical trial
-
Rhea-AI Summary
Alcyone Therapeutics Inc. (Alcyone) announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System (ThecaFlex) subcutaneous port and intrathecal catheter system for repeat intrathecal access, cerebrospinal fluid (CSF) aspiration, and delivery of SPINRAZA® (nusinersen) in spinal muscular atrophy (SMA) patients. The ThecaFlex device has the potential to significantly benefit patients with SMA who are being treated with SPINRAZA and are resistant to lumbar punctures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
clinical trial
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced FDA approval of WAINUA™ (eplontersen) for the treatment of hATTR-PN in adults. WAINUA demonstrated consistent and sustained benefit in halting neuropathy disease progression and improving quality of life. It will be available in the U.S. in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
Ionis Pharmaceuticals Inc

Nasdaq:IONS

IONS Rankings

IONS Stock Data

6.72B
144.54M
0.84%
101.07%
5.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Carlsbad

About IONS

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.